Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

Tercica Accessing $75M Via Equity-Based Line Of Credit

Oct. 18, 2005

By Jennifer Boggs

Tigris Series A Gets $11.6M For Topical Product In HPV

Oct. 17, 2005

By Jennifer Boggs

Tigris Series A Gets $11.6M For Topical Product In HPV

Oct. 17, 2005

By Jennifer Boggs

Koronis Working To Kill HIV By Increasing Viral Mutations

Oct. 14, 2005

By Jennifer Boggs

Koronis Working To Kill HIV By Increasing Viral Mutations

Oct. 14, 2005

By Jennifer Boggs

Raven's Series D: $48M For RAV12 Cancer Trials

Oct. 13, 2005

By Jennifer Boggs

Raven's Series D: $48M For RAV12 Cancer Trials

Oct. 13, 2005

By Jennifer Boggs

Praecis Continues Cost-Cutting Efforts, Sells Research Facility

Oct. 12, 2005

By Jennifer Boggs

CepTor Adding $20M To Test Myodur In Muscular Dystrophy

Oct. 12, 2005

By Jennifer Boggs

CepTor Adding $20M To Test Myodur In Muscular Dystrophy

Oct. 12, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.